Journal of Oncology

Role of the Microenvironment in Gastrointestinal Tumors


Publishing date
01 Oct 2019
Status
Published
Submission deadline
24 May 2019

1University of Oklahoma Health Sciences Center, Oklahoma City, USA

2Capital Medical University, Beijing, China

3University of Munich, Munich, Germany

4Mayo Clinic, Rochester, USA

5Augusta University, Augusta, USA


Role of the Microenvironment in Gastrointestinal Tumors

Description

The gastrointestinal (GI) tract maintains a complex environment with diverse epithelial and nonepithelial cell types that regulate discrete and distant processes. Infection and inflammatory conditions such as colitis, Barrett’s esophagus, and pancreatitis are linked to GI cancers, and introduction of a single targeted mutation in a specific cell type with or without inflammation can initiate cancer. Recent molecular subtyping studies using next-generation sequencing have expanded our understanding of GI cancers, and efforts to go beyond basic pathological assessment including multigene biomarkers, machine learning algorithms, and organoid drug screens are underway with promising results. Existing therapies including nucleoside analogs, targeted inhibitors, and monoclonal antibodies have demonstrated positive but limited results in patients, while newer therapies such as anti-PD1 immunotherapy have thus far shown benefit in subsets of patients without delivering the transformational results seen in other cancers. Previous work demonstrates that the tumor microenvironment (TME) is a major regulator of therapy resistance, antitumor immunity, and progression. To develop effective new therapies for GI cancers and accurately classify patient risk, an improved knowledge of molecular signaling and cell-cell interactions within the TME is needed. Importantly, in the current clinical context, a more complete understanding of how TME components modulate resistance to therapy and antitumor immunity will be fundamental to improving patient treatment options and outcomes.

This special issue seeks to improve understanding of the molecular, cellular, and pathological characteristics of the TME in GI cancers. This includes but is not limited to the role of specific TME cell types in therapy resistance (cancer stem cells, immune cells, tumor stroma, etc.), TME regulation of antitumor immunity, precancerous inflammation, novel TME-targeted therapies, TME molecular signaling, and clinical studies of the TME. We especially encourage original research articles that address therapy resistance and antitumor immunity in the context of signaling and interactions between discrete TME cell types, the use of TME-derived organoids for therapy resistance profiling and predicting patient outcomes, novel TME research methods, investigations of cancer stem cells and their functional components, bioinformatic studies of the TME, and novel biomarker concepts. We also enthusiastically welcome review articles that address the state of TME research, specific components of the TME, the clinical significance of the TME in therapy resistance, and TME-focused therapies.

Potential topics include but are not limited to the following:

  • Investigations of the TME’s role in therapy resistance
  • Characterization of TME-based regulation of antitumor immunity
  • In vivo or in vitro studies of TME-targeted therapies to overcome resistance
  • Characterization of TME alterations leading to GI carcinogenesis
  • Interactions between TME cell types in relation to GI cancer diagnosis and treatment
  • TME molecular signaling with relevance to GI tumor initiation or progression
  • Discovery of surrogate TME biomarkers and associated patient outcomes
  • Translational or clinical investigations of the TME in GI cancer
  • Epithelial-mesenchymal remodeling of the TME
  • Liquid biopsy approaches to detect components of the TME

Articles

  • Special Issue
  • - Volume 2019
  • - Article ID 2153413
  • - Editorial

Role of the Microenvironment in Gastrointestinal Tumors

Nathaniel Weygant | Yang Ge | ... | Kenneth J. Vega
  • Special Issue
  • - Volume 2019
  • - Article ID 6240505
  • - Review Article

The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective

Silvia Batista | Ana C. Gregório | ... | Bruno Costa-Silva
  • Special Issue
  • - Volume 2019
  • - Article ID 4835318
  • - Review Article

Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers

Yang Ge | C. Benedikt Westphalen | ... | Nathaniel Weygant
  • Special Issue
  • - Volume 2019
  • - Article ID 8585276
  • - Review Article

Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer

Valentin Vautrot | Gaëtan Chanteloup | ... | Jessica Gobbo
  • Special Issue
  • - Volume 2019
  • - Article ID 1079710
  • - Review Article

Gastric Cancer in the Era of Immune Checkpoint Blockade

Lucía Figueroa-Protti | Rebeca Soto-Molinari | ... | Warner Alpízar-Alpízar
  • Special Issue
  • - Volume 2019
  • - Article ID 7407190
  • - Review Article

Mechanisms of Metastasis in Colorectal Cancer and Metastatic Organotropism: Hematogenous versus Peritoneal Spread

E. Pretzsch | F. Bösch | ... | M. Angele
  • Special Issue
  • - Volume 2019
  • - Article ID 6402925
  • - Research Article

Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer

Dongfeng Qu | Nathaniel Weygant | ... | Courtney W. Houchen
  • Special Issue
  • - Volume 2019
  • - Article ID 4903152
  • - Research Article

MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction

Christina Just | Juliana Knief | ... | Christoph Thorns
  • Special Issue
  • - Volume 2019
  • - Article ID 2934925
  • - Research Article

Low Expression of GLIS2 Gene Might Associate with Radiosensitivity of Gastric Cancer

Haitong Sun | Jincheng Gu | ... | Zaixiang Tang
  • Special Issue
  • - Volume 2019
  • - Article ID 6270784
  • - Review Article

Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments

In-Hye Ham | Dagyeong Lee | Hoon Hur
Journal of Oncology
 Journal metrics
Acceptance rate24%
Submission to final decision66 days
Acceptance to publication37 days
CiteScore1.400
Impact Factor2.206
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.